Clinical Trial Assessing Quality of Life Improvement in dogs receiving supplement FucoPets® (Oligo Fucoidan)

Study Objective: 

Fucoidan, a polysaccharide found in algae, is know to produce a number of biologic anti-cancer effects, including inducing apoptosis along with inhibiting invasion, metastasis and angiogenesis of cancer cells.

Our current study is aimed at determining if giving cancer-bearing dogs a low-molecular weight fucoidan will enhance their quality of life. Our secondary objective is to determine if fucoidan has anti-cancer effects when used alone or with chemotherapy or radiation therapy.

This is a randomized blinded placebo controlled study. There will be a 2:1 ratio of treated to placebo controlled dogs. The study covers the cost of exams, blood work and some imaging (radiographs and/or ultrasound) when needed.

Eligibility Requirements: 

 

  • Any dog with histologic or cytologic confirmed cancer
  • CBC, serum biochemistry panel, Urinalysis, +/- thoracic radiographs, +/- abdominal U/S
  • Adequate renal, hepatic and hematologic parameters.
  • No steroids given within 7 days
  • No concurrent illness
  • Performance score of 0 or 1 with an expected survival time of over 6 weeks
Exclusion Criteria: 
  • Dogs currently taking any other supplement

  • Prior steroid use within the past 7 days

  • Liver values (ALT, AST) > 2 x ULN

  • Azotemia

  • Other clinical findings precluding the use of FucoPets® (Oligo Fucoidan)

Compensation: 
This is a fully funded study!
Location of Trial: 
Norwalk, CT

Click here for more information